Previous 10 | Next 10 |
2023-04-12 02:26:28 ET Summary The White House's announcement on drug price caps caused a significant drop in biopharma stocks during Q1 2023. The impact of drug pricing-related caps and pressure will likely be limited, and the industry is expected to adapt and find new revenue st...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings releas...
2023-03-29 04:02:00 ET Summary DEI is sometimes viewed as a 'softer' policy topic that doesn’t factor into investor outcomes. We think that’s a mistake. One of the most compelling reasons for implementing DEI initiatives is from a cost-management perspective. Reg...
2023-03-17 11:01:39 ET Truist has initiated IQVIA Holdings ( NYSE: IQV ) with a buy rating saying that the company is set to further benefit from its "differentiated" contract research organization ("CRO") segment. The firm has a $265 price target (~35% upside based on Thu...
In 2022, there was a decline of 1% in non-COVID trial activity compared to 2021, but using 2019 as the pre-pandemic baseline, there was an increase of 8% in trial activity in 2012. Clinical development productivity rebounded dramatically in 2022 with a 27% increase, reversing a 10-year do...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET. A live audio webcast of the pres...
Summary Despite a weak outlook for 2023 due to macro factors, IQV's revenue and EPS for Q4 2022 were better than expected. IQV is facing wage inflation pressures due to recruiting highly sought-after talent. I am recommending to go long on the basis of expected margin expansion (dri...
IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients. ...
For investors looking to double their money, look for healthcare stocks that are consistently increasing revenue and earnings per share (EPS). Cigna Group (NYSE: CI) , Danaher (NYSE: DHR) , and IQVIA Holdings (NYSE: IQV) all have managed to generate double-digit (o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare stocks are hot right now. The S&P 500 Health Care index has gained 3% over the last 12 months versus the 8% decline of the broader S&P 500 benchmark index . Reasons that healthcare stocks have outper...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...